BR112019014738A8 - Composto, forma de dosagem sólida, composição farmacêutica, forma cristalina de composto, método para tratar infecção por hepatite c ou uma condição resultante de uma infecção por hepatite c, composto da fórmula, e, uso de um composto da fórmula - Google Patents

Composto, forma de dosagem sólida, composição farmacêutica, forma cristalina de composto, método para tratar infecção por hepatite c ou uma condição resultante de uma infecção por hepatite c, composto da fórmula, e, uso de um composto da fórmula

Info

Publication number
BR112019014738A8
BR112019014738A8 BR112019014738A BR112019014738A BR112019014738A8 BR 112019014738 A8 BR112019014738 A8 BR 112019014738A8 BR 112019014738 A BR112019014738 A BR 112019014738A BR 112019014738 A BR112019014738 A BR 112019014738A BR 112019014738 A8 BR112019014738 A8 BR 112019014738A8
Authority
BR
Brazil
Prior art keywords
compound
infection
formula
hepatitis
solid dosage
Prior art date
Application number
BR112019014738A
Other languages
English (en)
Other versions
BR112019014738B1 (pt
BR112019014738A2 (pt
Inventor
Moussa Adel
Sommadossi Jean-Pierre
Original Assignee
Atea Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atea Pharmaceuticals Inc filed Critical Atea Pharmaceuticals Inc
Publication of BR112019014738A2 publication Critical patent/BR112019014738A2/pt
Publication of BR112019014738A8 publication Critical patent/BR112019014738A8/pt
Publication of BR112019014738B1 publication Critical patent/BR112019014738B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

É descrito um sal de hemissulfato da estrutura: para tratar um hospedeiro infectado com hepatite C, bem como composições farmacêuticas e formas de dosagem, incluindo formas de dosagem sólidas do mesmo.
BR112019014738-1A 2017-02-01 2018-01-31 Compostos, seus usos e composição os compreendendo BR112019014738B1 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762453437P 2017-02-01 2017-02-01
US62/453,437 2017-02-01
US201762469912P 2017-03-10 2017-03-10
US62/469,912 2017-03-10
US201762488366P 2017-04-21 2017-04-21
US62/488,366 2017-04-21
US201762575248P 2017-10-20 2017-10-20
US62/575,248 2017-10-20
PCT/US2018/016301 WO2018144640A1 (en) 2017-02-01 2018-01-31 Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus

Publications (3)

Publication Number Publication Date
BR112019014738A2 BR112019014738A2 (pt) 2020-03-10
BR112019014738A8 true BR112019014738A8 (pt) 2022-10-11
BR112019014738B1 BR112019014738B1 (pt) 2023-07-04

Family

ID=

Also Published As

Publication number Publication date
IL268077A (en) 2019-09-26
EP3577124A4 (en) 2021-01-06
KR102335193B1 (ko) 2021-12-03
IL295609A (en) 2022-10-01
US20200331954A1 (en) 2020-10-22
IL295609B1 (en) 2023-07-01
GEP20237457B (en) 2023-01-10
KR20230151050A (ko) 2023-10-31
ZA201904336B (en) 2020-12-23
RU2019127284A (ru) 2021-03-02
US20180215776A1 (en) 2018-08-02
JP2020505423A (ja) 2020-02-20
RU2019127284A3 (pt) 2021-08-04
MX2019009114A (es) 2019-10-09
CN110248951A (zh) 2019-09-17
TWI808072B (zh) 2023-07-11
TW201832770A (zh) 2018-09-16
EP3577124A1 (en) 2019-12-11
CA3048033C (en) 2023-06-20
TW202337472A (zh) 2023-10-01
WO2018144640A1 (en) 2018-08-09
CN115477679A (zh) 2022-12-16
KR20190113864A (ko) 2019-10-08
CA3197567A1 (en) 2018-08-09
US20200087339A1 (en) 2020-03-19
UA127407C2 (uk) 2023-08-16
SG11201906163TA (en) 2019-08-27
US10519186B2 (en) 2019-12-31
SG10202012214WA (en) 2021-01-28
IL295609B2 (en) 2023-11-01
AU2022271421A1 (en) 2022-12-22
PH12019550113A1 (en) 2019-12-02
AU2018215203B2 (en) 2022-12-08
US20210087217A1 (en) 2021-03-25
CN110248951B (zh) 2022-10-28
US10906928B2 (en) 2021-02-02
AU2018215203A1 (en) 2019-07-18
IL288737A (en) 2022-02-01
KR20210151247A (ko) 2021-12-13
NZ754996A (en) 2022-03-25
US10894804B2 (en) 2021-01-19
ZA202207262B (en) 2023-11-29
US20210277045A1 (en) 2021-09-09
IL268077B (en) 2022-01-01
CO2019009215A2 (es) 2019-08-30
ZA202104494B (en) 2023-01-25
KR102592899B1 (ko) 2023-10-24
IL288737B (en) 2022-09-01
MX2022009352A (es) 2022-09-02
CA3048033A1 (en) 2018-08-09
US20240018179A1 (en) 2024-01-18
BR112019014738A2 (pt) 2020-03-10
JP7066728B2 (ja) 2022-05-13
JP2022078216A (ja) 2022-05-24

Similar Documents

Publication Publication Date Title
BR112018070602A2 (pt) composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
BR112017000550A2 (pt) compostos antiproliferativos e métodos de uso dos mesmos
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112015021027A8 (pt) compostos terapêuticos, seus usos, e composições farmacêuticas
CO2020001244A2 (es) Derivados de quinolina para tratar infecciones con helmintos
UY37480A (es) Nuevos derivados de quinolina
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
BR112017016006A2 (pt) composto, composição farmacêutica, método de tratamento de doenças e condições, uso de um composto e de uma combinação, e, combinação.
BR112016023558A2 (pt) compostos úteis como imunomoduladores
CO2019009215A2 (es) Sal hemi-sulfato de nucleótido para el tratamiento del virus de la hepatitis c
CL2014000311A1 (es) Compuestos derivados de benzotiazepinas sustituidas; composicion farmaceutica que los contiene; y su uso para el tratamiento o profilaxis de la infeccion del virus sincicial respiratorio.
BR112016011065A8 (pt) composto cristalino, composição farmacêutica, forma de dosagem, método para tratar anemia
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
BR112017001565A2 (pt) ?composto, métodos para tratar uma infecção e para fabricar um medicamento, composição farmacêutica, e, uso de um composto?
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
DOP2016000253A (es) Nuevos compuestos
BR112018003827A2 (pt) composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição.
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
BR112014019584A8 (pt) Composto da fórmula (i), sua forma tautomérica, seu isômero, ou seu sal farmaceuticamente aceitável, composição farmacêutica, método de inibição da replicação de um vírus contendo rna, método de tratamento ou prevenção de infecção causada por um vírus contendo rna, e, método de tratamento de infecção por hepatite c
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
BR112017003242A2 (pt) composto, métodos para tratar infecção por vírus e para fabricação de um medicamento, composição farmacêutica, e, uso de um composto.
EA201892246A1 (ru) Производные аминотиазола, полученные в качестве противовирусных средств
BR112018070536A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07F 9/6521 , C07F 9/6558

Ipc: C07F 9/6521 (2006.01), C07F 9/6558 (2006.01), A61K

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023001232-1 PROTOCOLO 870230006242 EM 23/01/2023 17:22.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/01/2018, OBSERVADAS AS CONDICOES LEGAIS